ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00401011
Recruitment Status : Completed
First Posted : November 17, 2006
Last Update Posted : February 23, 2018
Sponsor:
Information provided by (Responsible Party):
AEterna Zentaris

Brief Summary:
This is a phase I/II study of perifosine in combination with bortezomib—with or without dexamethasone—for patients with relapsed or refractory multiple myeloma previously treated with bortezomib. The current protocol will enroll patients with relapsed or refractory multiple myeloma who have been previously treated with bortezomib. The patients will be treated with perifosine, 50 mg or 100 mg qhs, in combination with bortezomib to determine if there is any preliminary evidence that the addition of perifosine improves the outcome for these patients. Previous treatment with perifosine will be allowed in this study. Patients progressing on treatment with perifosine and bortezomib will receive dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 of each 21-day cycle in addition to bortezomib and perifosine.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Multiple Myeloma in Relapse Drug: Perifosine Drug: Bortezomib Drug: Dexamethasone Phase 1 Phase 2

Detailed Description:

The primary objective of the phase I portion is to determine the maximum tolerated dose of perifosine in combination with bortezomib in patients previously treated with bortezomib.

All patients will receive daily perifosine qhs with food. In the initial phase I study, 3 patients will be entered into a specified combination of perifosine and bortezomib cohorts. If no dose-limiting toxicity is observed, then three additional patients will be entered in cohort 4 - a full dose of bortezomib (1.3 mg/m2 on days 1, 4, 8 and 11 every 3 weeks). If this dose is tolerated it will be used for the phase II study, otherwise an intermediate dose of 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks will be employed.

The phase II study will use the maximum tolerated dose of bortezomib and perifosine. The primary objective of phase II portion is to determine the response rate (the combined CR + PR + MR) following treatment with perifosine + bortezomib in patients with multiple myeloma who have relapsed following initial front-line therapy, are refractory to their most recent therapy, and were previously treated with bortezomib. The secondary objectives of the phase II portion are;

  1. To further assess the safety and tolerability of perifosine in combination with bortezomib—with or without dexamethasone—in patients with multiple myeloma.
  2. To obtain correlative data in patients with multiple myeloma treated with perifosine in combination with bortezomib—with or without dexamethasone (NOTE Centers may choose not to participate in correlative studies).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 84 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: In the Phase I part, maximum tolerated dose (MTD) is determined in sequential cohorts of patients. All patients will start with perifosine and bortezomib (cf. arms and interventions). In case of progression, dexamethasone 20 mg will be added to treatment. Phase II: open-label single treatment arm.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Phase I/II Study of the Safety and Efficacy of Perifosine and Bortezomib With or Without Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Bortezomib
Study Start Date : August 2006
Actual Primary Completion Date : December 2010
Actual Study Completion Date : July 2011


Arm Intervention/treatment
Experimental: Phase II: Perifosine + Bortezomib
All patients will start with perifosine at bedtime daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days. Patients will be evaluated at q 3 weeks. If the patient has a CR, PR, MR or stable disease, they will continue treatment.
Drug: Perifosine

Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.

Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.

Other Names:
  • D-21266
  • KRX-0401
Drug: Bortezomib
Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
Other Name: Velcade
Experimental: Phase II: Perifosine + Bortezomib + Dexa
If the patient shows progressive disease, dexamethasone 20 mg will be added on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
Drug: Perifosine

Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.

Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.

Other Names:
  • D-21266
  • KRX-0401
Drug: Bortezomib
Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
Other Name: Velcade
Drug: Dexamethasone
Phase II: If the patient shows progressive disease after 3 weeks, dexamethasone 20 mg will be added to perifosine and bortezomib on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
Other Name: Dexa
Experimental: Phase I: Dose 1: Perifosine + Bortezomib
Perifosine 50 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks.
Drug: Perifosine

Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.

Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.

Other Names:
  • D-21266
  • KRX-0401
Drug: Bortezomib
Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
Other Name: Velcade
Experimental: Phase I: Dose 2: Perifosine + Bortezomib
Perifosine 100 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
Drug: Perifosine

Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.

Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.

Other Names:
  • D-21266
  • KRX-0401
Drug: Bortezomib
Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
Other Name: Velcade
Experimental: Phase I: Dose 3: Perifosine + Bortezomib
Perifosine 50 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
Drug: Perifosine

Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.

Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.

Other Names:
  • D-21266
  • KRX-0401
Drug: Bortezomib
Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
Other Name: Velcade
Experimental: Phase I: Dose 4: Perifosine + Bortezomib
Perifosine 100 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
Drug: Perifosine

Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.

Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.

Other Names:
  • D-21266
  • KRX-0401
Drug: Bortezomib
Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
Other Name: Velcade



Primary Outcome Measures :
  1. Phase I: Maximum Tolerated Dose (MTD). Phase II: To determine response rate. [ Time Frame: Every 3 weeks ]

    Phase I: To determine the MTD of perifosine in combination with bortezomib in patients previously treated with bortezomib.

    Phase II: The primary endpoint of the study was 6-month progression-free survival.



Secondary Outcome Measures :
  1. Phase II: Tolerability and Safety [ Time Frame: Every 3 weeks ]
    To assess the safety and tolerability of perifosine in combination with bortezomib — with or without dexamethasone.

  2. Phase II: Correlative data [ Time Frame: Every 3 weeks ]
    To obtain correlative data in patients with multiple myeloma treated with perifosine in combination with bortezomib—with or without dexamethasone



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject was previously diagnosed with multiple myeloma based on standard diagnostic criteria, as follows.

    Major criteria:

    • Plasmacytomas on tissue biopsy.
    • Bone marrow plasmacytosis (> 30% plasma cells).
    • Monoclonal immunoglobulin spike on serum electrophoresis immunoglobulin G (IgG) >3.5 g/dL or immunoglobulin A (IgA) > 2.0 g/dL; kappa or lambda light chain excretion > 1 g/day on 24 hour urine protein electrophoresis.

    Minor criteria:

    • Bone marrow plasmacytosis (10 to 30% plasma cells).
    • Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria.
    • Lytic bone lesions.
    • Normal IgM < 50 mg/dL, IgA < 100 mg/dL or IgG < 600 mg/dL.
  2. Any of the following sets of criteria will confirm the diagnosis of multiple myeloma:
  3. Any two of the major criteria.
  4. Major criterion 1 plus minor criterion b, c, or d.
  5. Major criterion 3 plus minor criterion a or c.
  6. Minor criteria a, b, and c or a, b, and d.
  7. Patients must have relapsed or refractory disease (refractory is defined as progression during treatment or within 60 days after the completion of treatment).
  8. Patients must have been previously treated with bortezomib. Patients may have received prior perifosine.
  9. Age >= 18 years at the time of signing informed consent document.
  10. All necessary baseline studies for determining eligibility must be obtained within 14 days prior to enrollment. (Pregnancy test must be within 7 days for women of childbearing potential.)
  11. Subject has an ECOG (Zubrod) performance status of 0 to 2.
  12. Subject must be able to adhere to the study visit schedule and other protocol requirements.
  13. Subject must understand and voluntarily sign an informed consent document.
  14. Women of child-bearing potential (WCBP)— must have a negative serum or urine pregnancy test within 72 hours prior to enrollment. In addition, all sexually active WCBP and male patients must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study.

Exclusion Criteria:

  1. Renal insufficiency (serum creatinine levels > 3 mg/dL).
  2. Patients who present with either ALT or AST >= 2.5 X upper limit of normal (ULN) and/or patients with bilirubin >= 1.5 X ULN.
  3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).
  4. Concomitant medications that include corticosteroids (except as indicated for other medical conditions or up to 100 mgs of hydrocortisone or equivalent as premedication for administration of certain medications or blood products), chemotherapy, or other therapy that is or may be active against myeloma within 2 weeks prior to Cycle 1 Day 1. Nitrosoureas must be discontinued 6 weeks prior to Cycle 1 Day 1.
  5. Subjects with hemoglobin < 8.0 g/dL.
  6. Subjects with an absolute neutrophil count (ANC) <= 500 cells/mm3.
  7. Peripheral neuropathy of grade 3 or greater. Patients with painful grade 2 neuropathy are also excluded.
  8. Subjects with evidence of mucosal or internal bleeding and/or platelet refractory (i.e., unable to maintain a platelet count >= 50,000 cells/mm3).
  9. Previous history of intolerance of bortezomib or perifosine.
  10. Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study.
  11. WCBP who are pregnant or breast-feeding or men and women who are not using adequate contraception.
  12. Plasma cell leukemia at time of study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00401011


Sponsors and Collaborators
AEterna Zentaris
Investigators
Principal Investigator: Paul Richardson, MD Dana-Farber Cancer Institute

Publications of Results:
Responsible Party: AEterna Zentaris
ClinicalTrials.gov Identifier: NCT00401011     History of Changes
Other Study ID Numbers: Perifosine 218
First Posted: November 17, 2006    Key Record Dates
Last Update Posted: February 23, 2018
Last Verified: February 2012

Keywords provided by AEterna Zentaris:
Perifosine
Bortezomib
Dexamethasone
Relapsed or Refractory Multiple Myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
Dexamethasone
Bortezomib
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors